247 related articles for article (PubMed ID: 35542993)
1. Aducanumab: Appropriate Use Recommendations Update.
Cummings J; Rabinovici GD; Atri A; Aisen P; Apostolova LG; Hendrix S; Sabbagh M; Selkoe D; Weiner M; Salloway S
J Prev Alzheimers Dis; 2022; 9(2):221-230. PubMed ID: 35542993
[TBL] [Abstract][Full Text] [Related]
2. Lecanemab: Appropriate Use Recommendations.
Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
[TBL] [Abstract][Full Text] [Related]
3. Aducanumab: Appropriate Use Recommendations.
Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
[TBL] [Abstract][Full Text] [Related]
5. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.
Loomis SJ; Miller R; Castrillo-Viguera C; Umans K; Cheng W; O'Gorman J; Hughes R; Budd Haeberlein S; Whelan CD
Neurology; 2024 Feb; 102(3):e207919. PubMed ID: 38165296
[TBL] [Abstract][Full Text] [Related]
6. Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.
Howe MD; Britton KJ; Joyce HE; Pappas GJ; Faust MA; Dawson BC; Riddle MC; Salloway SP
J Prev Alzheimers Dis; 2023; 10(4):765-770. PubMed ID: 37874098
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
Withington CG; Turner RS
Front Neurol; 2022; 13():862369. PubMed ID: 35401412
[TBL] [Abstract][Full Text] [Related]
8. A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
Muralidharan KK; Karumanchi S; Kowalski KG; Burkett P; Chapel S; Rajagovindan R; Nestorov I
J Clin Pharmacol; 2022 Aug; 62(8):1030-1046. PubMed ID: 35285968
[TBL] [Abstract][Full Text] [Related]
9. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
10. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi M; Cecchetti G; Spinelli EG; Vezzulli P; Falini A; Agosta F
JAMA Neurol; 2022 Mar; 79(3):291-304. PubMed ID: 35099507
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
[TBL] [Abstract][Full Text] [Related]
13. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.
Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Love N; Singhal A
Radiol Case Rep; 2023 Jan; 18(1):275-279. PubMed ID: 36388611
[TBL] [Abstract][Full Text] [Related]
14. Aducanumab: Appropriate use recommendations.
Cummings J; Salloway S
Alzheimers Dement; 2022 Mar; 18(3):531-533. PubMed ID: 34314093
[No Abstract] [Full Text] [Related]
15. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.
VandeVrede L; Gibbs DM; Koestler M; La Joie R; Ljubenkov PA; Provost K; Soleimani-Meigooni D; Strom A; Tsoy E; Rabinovici GD; Boxer AL
Alzheimers Dement (Amst); 2020; 12(1):e12101. PubMed ID: 33072846
[TBL] [Abstract][Full Text] [Related]
16. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
[TBL] [Abstract][Full Text] [Related]
17. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
18. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]